In line with our previous observations, the anti-RANKL treatment markedly enhanced SERCA activity and SERCA2a protein content, which may potentially improve Ca2+ homeostasis, impacting the progression of cardiac hypertrophy by enhancing cardiomyocyte contractility. This evidence concerns the gene TNFSF11 and cardiac hypertrophy.